DREAM News
February 26, 2019

PrecisionFDA and NCI CPTAC Announce the Best Performers in Multi-omics Sample Mislabeling Big Data Challenge

PrecisionFDA and the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) (in coordination with DREAM Challenges) are pleased to announce the Best Performers in the first-ever Crowdsourced Multi-omics Sample Mislabeling Big Data Challenge. This unique challenge utilized proteogenomic datasets generated by CPTAC and clinical annotation information. A total of 230 submissions from participants around the globe were received and evaluated. Subchallenge 1 focused on the development of next-gen computational models for detecting mislabeled samples using proteomic and clinical data generated by CPTAC, while Subchallenge 2 took a step further, aiming to identify and correct mismatched samples with one data type mislabeled among three data types (clinical, transcriptomic, and proteomic data). Visit us to learn more about this big data computational multi-omics challenge and its best performers and come here them their findings at  DREAM Challenges@RECOMB 2019. (learn more)